 Home > Active Ingredient News > Drugs Articles > A-share/Hong Kong stocks leading pharmaceutical companies: the latest panoramic layout of Hengrui and Hausen large and small molecules

A-share/Hong Kong stocks leading pharmaceutical companies: the latest panoramic layout of Hengrui and Hausen large and small molecules

 Last Update: 2021-08-05
 Source: Internet
 Author: User

Tags

ibuprofen anti inflammatory drug

pharmaceutical companies india

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

The names of "Hengrui Pharmaceutical" and "Hausen Pharmaceutical/Hansen Pharmaceutical" are well known in the Chinese pharmaceutical market

Below, with the data of Pharnexcloud ( let’s take a look at what Hengrui/Hausen’s product line looks like? (The details are subject to the company’s official disclosure)

01 Antibody/Macromolecule Field:

siRNA/ASO/mRNA therapy, cell therapy, TIGIT double antibody, Alzheimer's SHR1707 (β-amyloid monoclonal antibody), TSLP, CEA-ADC, Titin/Obscurinc polypeptide bispecific antibody platform, cMET-ADC, PD-L1/CD47, CD3+ multispecific antibody, VEGF/ANG2, PEG-IL-2, CTGF, B7H3-ADC, TROP-2 ADC, CD3/B7H3, CLDN18.

02Small molecule field:

Layout PROTAC, GLP-1/GCGR, CD73 small molecules, TLR7, ROR, oxytocin antagonists, SHP2, KRAS, FLT3, MCL-1 inhibitors;

SHR3680 (AR inhibitor, Phase 3 clinical), Famitinib (Phase 3 clinical), SHR6390 (CDK4/6, NDA), SHR2554 (EZH2 inhibitor), SHR7390 (MEK inhibitor), HRS2543 (ERK inhibitor) , SHR9549 (SERD, selective estrogen receptor degradation agent), SHR8554 (MOR target), SHR0410 (KOR target), HRS4800 (NaV1.

SHR8008 (a new oral antifungal drug introduced from Mycovia), TLR8 selective agonist HRS9950, hepatitis B virus (HBV) nucleocapsid assembly regulator HRS5091, monophosphoramide monoester tenofovir prodrug SHR10234, Noliglycopeptide (GLP-1), SHR5126 (A2aR inhibitor), oral GLP-1;

NOV03 eye drops (perfluorohexyl octane) (Hengrui code name is SHR8058), ROMK target antihypertensive drug, CyclASol (0.

01Small molecule field:

GLP-1/GIP, PD-L1 small molecules, IRAK4, TYK2, P2X3 inhibitors, PI3K, FGFR4, ERK, SHP2, KRAS, BRD4, PI3Kα, EGFR/HER2, NK receptor antagonists, ASK1 ACC FXR in the field of NASH , G protein coupled receptor modulators and so on

In February 2021, Hausen Pharmaceuticals and Synexis signed an exclusive license and cooperation agreement to obtain the exclusive rights to develop and commercialize ibrexafungerp in Greater China

On July 29, 2020, Terns Pharmaceuticals and Hansen Pharmaceuticals/Hausen Pharmaceuticals signed a TRN-000632 exclusive product licensing cooperation agreement in Greater China

FGF21 fusion protein, CD47 double antibody (PD-L1/CD47 fusion protein), B7H4 antibody, TROP2 antibody and ADC, BCMA antibody, B7H4- ADC, GPC3 antibody

On May 28, 2019, Hausen Pharmaceuticals and Viela Bio reached a strategic cooperation to introduce the development and commercialization rights of the CD19 monoclonal antibody Inebilizumab in China with a milestone payment of US$220 million.

On January 6, 2021, the clinical application of Hausen Pharmaceuticals' biopharmaceuticals was accepted and announced by NMPA/CDE.

▲Yaorongyun data, clinical registration

Pharmacy Cloud data ( shows that Hausen Pharmaceuticals first established a biopharmaceutical research and development center in 2016, applying international cutting-edge technologies to develop and industrialize innovative biopharmaceuticals.
Products cover tumors, autoimmunity, and metabolism.
In the field of diseases and other diseases, an advanced biological drug research and development platform that meets GMP standards has been established
.
On January 28, 2021, the Biopharmaceutical R&D Center of Shanghai Hansen Biomedical Technology Co.
, Ltd.
was officially launched
.
In addition, the company's biomedicine industrialization landed in Changzhou Hengbang
.

03Other transactions/BD/cooperation include:

Hausen license out the company’s original third-generation EGFR new drug at EQRx in the United States, cooperated with AI pharmaceutical company Atomwise to develop new drugs, and established a joint venture to establish Bosheng Pharmaceutical
.

On June 16, 2021, Hansen Pharmaceuticals and Cormorant Asset Management (Cormorant Asset Management) co-founded and incubated Blossom Biosciences (Blossom Biosciences) announced the establishment
.
Bosheng Pharmaceutical is committed to bringing potential breakthrough therapeutics to more Chinese patients.
It has now completed a US$72 million Series A financing jointly led by Hansen Pharmaceutical and Osprey Asset Management
.
Bosheng Pharmaceutical has reached an agreement with Hansen Pharmaceutical to provide preclinical, clinical and commercial support to Hansen Pharmaceutical to accelerate the development and launch of the product pipeline in China
.
Osprey Asset Management will support Bosheng Pharmaceutical to introduce innovative products through its rich global biomedical resources and portfolio companies
.

refer to:

NMPA/CDE;

Pharmacy Cloud Data Cloud Data FDA/EMA;

FDA/EMA;

Public disclosure by related companies;

http:// Tuojie Biology, https:// Biology, https:// http:// http://cn.
reistonebio.
com/;

http://cn.
reistonebio.
com/;

https:// and so on
.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.